☰

Pharvaris

Updating the operating model

Industry
Biotechnology
Public information as of
January 2026

A4BEE prepared this analysis from publicly available sources. It reflects our own reading of Pharvaris's published strategy and is not endorsed by, or produced in cooperation with, Pharvaris. Company website

Strategic priorities

Pharvaris operates across 4 stated priorities, with the most concrete near-term plan anchored on commercial readiness by 2026.

Submit IR capsule NDA in 1H 2026 and ER tablet NDA shortly after, building complete U.S. commercial infrastructure to support the global launch of deucrictibant.

Displace the injectable-centric standard of care with oral deucrictibant, providing patients with convenient prophylactic and on-demand treatment options.

Initiate the CREAATE study in 2025 to expand into AAE-C1INH and explore other bradykinin-mediated diseases beyond hereditary angioedema.

Challenges we see

  • Operations Manufacturing

    CMC Validation and Dual-Formulation Scale-Up

    Managing manufacturing scale-up for both the 20 mg IR capsule and 40 mg ER tablet requires parallel supply chains with different technical requirements. The ER formulation uses an extended-release matrix sensitive to manufacturing variability.

    Risk of batch failures due to manufacturing variability in the extended-release matrix, potentially delaying NDA submission and market entry.

  • Digital Integration

    CDMO Visibility Gap

    As a virtualized manufacturer using outsourced GMP manufacturing, Pharvaris lacks direct visibility into production floor operations. Data from manufacturing runs is siloed within third-party systems.

    Delayed identification of quality excursions and inability to proactively address manufacturing issues before they impact product quality.

  • Digital Operations

    Fragmented Data Landscape

    Clinical trial data, pharmacokinetic modeling data, and CMC validation data exist in separate islands, hindering generation of a unified source of truth for regulatory submissions.

    Slow NDA compilation and risk discrepancies in data-from-source-to-scientist that could result in FDA or EMA warning letters.

  • Digital Regulatory

    Third-Party Cybersecurity Vulnerability

    Internal computer systems and those of third-party CMOs, CROs and consultants are acknowledged as vulnerable to computer viruses and disruptions, creating material risk to product development programs.

    Ransomware attacks or data leaks involving sensitive Phase 3 patient data could delay clinical trials and damage company reputation.

  • Compliance Regulatory

    Regulatory Compliance and ESG Pressures

    The 1H 2026 deadline for NDA submission combined with emerging ESG reporting mandates under Swiss and EU regulations create overlapping compliance requirements demanding rigorous data governance.

    Any data integrity discrepancy could result in regulatory rejection, while Compliance gaps with ESG mandates by 2030 could trigger fines and reputational damage.

Opportunities, by urgency and business impact

Each bubble is one opportunity, numbered to match the list below. Further right means it bites sooner; higher means a bigger effect on the business. A bigger bubble means a bigger implementation effort.

Source: A4BEE analysis of public sources

  1. Manufacturing Floor Visibility

    Pharvaris operates through distributed CDMOs but lacks real-time visibility into manufacturing operations, leading to delayed quality excursion detection and reactive rather than proactive production management.

    Implement an Industrial Data Platform using OPC UA protocols to provide real-time batch health dashboards, enabling the Technical Operations team to monitor CDMO production cycles and identify issues before they impact product quality.

  2. Lab Digitalization and Audit Readiness

    The Leiden translational research hub relies on paper-based workflows for complex biomarker assays, creating audit risks and fragmenting critical R&D data needed for regulatory filings.

    Deploy a Digital Lab solution to transition from source-to-scientist data capture, ensuring kinin biomarker data is automatically captured, contextualized, and audit-ready for FDA submission.

  3. Unified Regulatory Data Platform

    Clinical trial data, PK modeling data, and CMC validation data exist in separate silos, creating inefficiencies in NDA compilation and risk of data discrepancies during regulatory review.

    Build an ontology-based data lakehouse that serves as the single source of truth, automatically contextualizing data from diverse sources and enabling near real-time regulatory analytics.

  4. IT/OT Security Convergence

    Disconnect between corporate IT infrastructure and operational technology at CDMO sites creates cybersecurity vulnerabilities and hampers integrated data governance across the supply chain.

    Implement a secure IT/OT convergence framework with zero-trust architecture, protecting sensitive clinical and manufacturing data while enabling smooth data flow between Pharvaris and manufacturing partners.

  5. Commercial Supply Chain Readiness

    Transition from clinical supply to commercial supply requires massive upgrade in logistics software to manage specialty pharmacy networks and controlled distribution for the 2027 launch.

    Deploy digital twins of the supply chain to simulate specialty pharmacy demand surges and optimize inventory levels, reducing risk of stockouts for life-saving HAE medication.

What we'd propose

  • Enterprise AI

    CDMO Industrial Data Platform

    End-to-end manufacturing visibility platform connecting Pharvaris to its CDMO network via OPC UA, providing real-time batch health monitoring and predictive quality analytics.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital Lab

    Digital Lab Transformation for Translational Research

    Comprehensive lab digitalization program for the Leiden R&D hub, automating biomarker assay workflows and ensuring regulatory-compliant data capture from source to scientist.

    • Unified data backbone

      Connect instruments and LIMS into a single data spine so QC and CDMO records are queryable across sites.

      DETAIL

    • Paperless workflows

      Move lab execution from paper to instrument-captured records with full audit trail.

      DETAIL

    • Continuous QC release

      Review-by-exception dashboards that flag only the records needing scientist attention.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital Lab
  • Enterprise AI

    Regulatory Data Lakehouse Platform

    Ontology-driven unified data platform integrating clinical, PK modeling, and CMC data streams into a single source of truth for NDA submission and ongoing regulatory compliance.

    • Ontology layer

      A shared semantic model so lab, process, and quality data describe the same things the same way.

      DETAIL

    • Predictive models

      Models trained on the historical data plane that flag deviations before they become scrap.

      DETAIL

    • Decision surfaces

      Single pane of glass that surfaces model output to the right role at the right moment.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Enterprise AI
  • Digital CDMO

    Secure IT/OT Convergence Framework

    Enterprise-grade cybersecurity architecture bridging corporate IT and CDMO operational technology, implementing zero-trust principles and IEC 62443 compliance.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO
  • Digital CDMO

    Digital Twin Supply Chain Optimization

    AI-powered supply chain simulation platform enabling demand forecasting, inventory optimization, and distribution network planning for commercial launch readiness.

    • OT/IT convergence

      Pull sensor and controller data off the line into a shared data plane in real time.

      DETAIL

    • Batch intelligence

      Golden-batch comparison and deviation detection running on the same data plane.

      DETAIL

    • Production release flow

      Closed-loop between QA, MES, and ERP so batch record review and release follow the data, not the paperwork.

      DETAIL

    • Shorter lead time from data capture to decision.
    • Records that audit on their own, not on inspection day.
    • Scale without adding the same headcount.

    We've done this before

    See how we do Digital CDMO

Digital maturity: today and target

Scored out of 100 across six dimensions. The target is what Pharvaris's own published ambition implies — not a perfect score.

Source: A4BEE analysis of public sources
Manufacturing Visibility 25 → 80
Virtualized CDMO model lacks real-time floor data; requires OPC UA integration
Lab Digitalization 35 → 85
Leiden R&D relies on paper-based workflows; needs automated data capture
Data Integration 30 → 90
Clinical, PK, and CMC data in silos; requires unified lakehouse platform
Cybersecurity Maturity 40 → 85
IT/OT disconnect acknowledged; needs zero-trust framework implementation
Supply Chain Analytics 20 → 75
Clinical supply mode; requires commercial-scale digital twin capabilities
Regulatory Compliance Automation 35 → 90
Manual NDA compilation; needs automated data pipelines and audit trails

Check this yourself

Our Service Portal has free self-assessments and market comparisons. These are the ones that line up with what we've read above — no sales call required.

Think we've read this right?

Talk to us

Related reading

This is an independent analysis prepared by A4BEE from publicly available information as of January 2026. It reflects A4BEE's own interpretation and opinion, is not affiliated with, endorsed by, or verified with Pharvaris, and may be incomplete or inaccurate. All company names and trademarks are the property of their respective owners. To request a correction or removal, contact [email protected].